A randomized, double-blind, crossover comparative endoscopy study on the gastroduodenal tolerability of a highly specific cyclooxygenase-2 inhibitor, flosulide, and naproxen

Scandinavian Journal of Gastroenterology

Volumn 32, Issue 2, 1997, Pages 126-130

  Bjarnason, I ^a   Macpherson, A ^b   Rotman, H ^b   Schupp, J ^b   Hayllar, J ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b NONE

Author keywords

Cyclooxygenase inhibition; Drug toxicity; Nonsteroidal anti inflammatory drugs

Indexed keywords

FLOSULIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN SYNTHASE INHIBITOR;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DYSPEPSIA; ENDOSCOPY; FEMALE; FLATULENCE; GASTRITIS; HUMAN; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; OSTEOARTHRITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031016921     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365529709000182     Document Type: Article

References (38)

1. Barrier CH, Hirschowitz BI. Current controversies in rheumatology. Controversies and management of non-steroidal anti-inflammatory drug induced side effects on upper gastrointestinal tract. Arthritis Rheum 1989;32:926-9.
2. Armstrong CP, Blower AL. Nonsteroidal anti-inflammatory drugs and life threatening complications of peptic ulcer disease. Gut 1987;28:527-32.
3. Bjarnason I, Hayllar J, Macpherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine. Gastroenterology 1993;104:1832-47.
4. Somasundaram S, Hayllar J, Rafi S, Wrigglesworth J, Macpherson A, Bjarnason I. The biochemical basis of induced damage to the gastrointestinal tract: a review and a hypothesis. Scand J Gastroenterol 1995;30:289-99.
5. Wallace JL. Non-steroidal anti-inflammatory drug gastropathy and cytoprotection: pathogenesis and mechanisms re-examined. Scand J Gastroenterol 1992;27 Suppl 192:3-8.
6. Wallace JL, Granger DN. Pathogenesis of NSAID gastropathy: are neutrophils the culprits? Trends Pharmacol Sci 1992;13:129-30.
7. Whittle BJR. Protective mechanisms of the gastric mucosa. In: Gustsavsson S, Kumar D, Graham DY, editors. The stomach. Edinburgh: Churchill Livingstone, 1992:81-101.
8. Rainsford KD. Mechanisms of gastrointestinal toxicity of nonsteroidal anti- inflammatory drugs. Scand J Gastroenterol 1989; 24 Suppl 163:9-16.
9. Hayllar J, Macpherson A, Bjarnason I. Gastroprotection and nonsteroidal anti-inflammatory drugs. Drug Safety 1992;7:86-105.
10. Fern GC. Controversies in NSAID-induced gastroduodenal damage - do they matter? Aliment Pharmacol Ther 1994;8:15-26.
11. Wallace JL, Reuter B, Cicala C, McKnight W, Grisham MB, Cirino GA. A diclofenac derivative without ulcerogenic properties. Eur J Pharmacol 1994;257:249-55.
12. Wallace JL, Reuter B, Cicala C, McKnight W, Grisham MB, Cirino G. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in rat. Gastroenterology 1994;107:173-9.
13. Simmons D, Xie W, Evett G, Merrill J, Robertson DL, Bradshaw WS. Drug inhibition and cellular regulation of prostaglandin G/H synthase isoenzyme 2. J Lipid Med 1993;6:113-7,
14. Herschman H, Fletcher B, Kujubu D. TIS10. A mitogen-inducible glucocorticoid- inhibited gene that encodes a second prostaglandin synthase/cyclooxygenase enzyme. J Lipid Med 1993;6:89-99.
15. Mitchcll JA, Akarasereenout P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993;90:11693-7.
16. O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cycloozygenase-2 in human tissues. FEBS 1993;330:156-60.
17. Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995;83:473-82.
18. Maier JA, Hla T, Maciag T. Cyclooxygenase is an immediate-early gene induced by interleukin 1 in human endothelial cell. J Biol Chem 1992;265:10805-8.
19. Lee SH, Soyoola E, Chanmugam P, Hart S, Sun W, Zhong, H et al. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 1992;267;25934-8.
20. Vane JR. Towards a better aspirin. Nature 1994;367:215-6.
21. Hayllar J, Bjarnason I. NSAIDs, Cox-2 inhibitors, and the gut. Lancet 1995;346:521-2.
22. Vane JR, Botting RM. Overview-mechanisms of action of anti-inflammatory drugs. In: Vane JR, Botting J, Botting R, editors. Improved non-steroid anti-inflammatory drugs. Cox-2 enzyme inhibitors. Dordrecht: Kluwer Academic Publishers 1996:1-27.
23. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1995;68:6610-4.
24. Vane JR. NSAIDs, Cox-2 inhibitors, and the gut. Lancet 1995;346:1105-6.
25. Aslanian R, Carruthers NI, Kaminski J. Cyclooxygenase-2: a novel target for therapeutic intervention. Exp Opin Invest Drugs 1994;3:1323-5.
26. Wiesenberg-Boeettcher I, Schweizer A, Muller K. The pharmacologic profile of CGP 28238, a highly potent anti-inflammatory compound. Agents Actions 1989;26:240-2.
27. Wiesenberg-Boeettcher I, Schweizer A, Muller K, Maerki F, Pfeilschifter J. The pharmacological profile of CGP 28238, a novel highly potent anti-inflammatory compound. Drug Exp Clin Res 1989;15:501-9.
28. Lanza FL. Endoscopic studies of gastric and duodenal injury after the use of ibuprofen, aspirin, and other nonsteroidal anti-inflammatory agents. Am J Med 1984;77 Suppl 1 A: 19-24.
29. Lanza FL, Graham DY, Davis RE, Rack MF. Endoscopic evaluation of cimethidine and sucralfate for prevention of naproxen-induced gastroduodenal injury: effects of scoring method. Dig Dis Sci 1990;35:1494-9.
30. Farkad E, Whitehead J. Statistics in medicine 1991;10:901-7.
31. Klein T, Nusing RM, Pfeilschifter J, Ullrich V. Selective inhibition of cyclooxygenase 2. Biochem Pharmacol 1994;48:1605-10.
32. Bardhan KD, Bjarnason I, Scott DL, Griffin WM, Fenn GC, Shield MJ, et al. The prevention and healing of acute NSAID-associated gastroduodenal mucosal damage by misoprostol. Br J Rheumatol 1993;32:990-5.
33. Giercksky KE, Huseby G, Rugstad HE. Epidemiology of NSAID-related gastrointestinal side effects. Scand J Gastroenterol 1989;24 Suppl 163:3-8.
34. Rodrigues LAG, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769-72.
35. Langman MJS, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RFA, et al. Risk of bleeding peptic ulcers associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:1075-8.
36. Lanza FL, Rack MF, Lynn M, Wolf BS, Sanda M. An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen and placebo on the gastrointestinal mucosa. J Rheumatol 1987;14:338-41.
37. Trondstad RI, Aadland E, Holler T, Olaussen B. Gastroscopic findings after treatment with enteric coated and plain naproxen tablets in healthy subjects. Scand J Gastroenterol 1985;20:239-42.
38. Mahmod T, Rafi S, Scott D, Wrigglesworth JM, Bjarnason I. NSAIDs and uncoupling of mitochondrial oxidative phosphorylation. Arth Rheumat 1996. In press.